May 10 |
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript
|
May 9 |
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
|
May 9 |
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
|
May 8 |
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
|
Apr 30 |
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
|
Apr 25 |
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
|
Apr 11 |
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
|
Apr 2 |
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
|
Mar 10 |
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
|